UPM Pharmaceuticals, Inc

upm-inc.com

UPM Pharmaceuticals is a Bristol Tennessee based contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

CAPSIDA BIOTHERAPEUTICS AND ABBVIE ANNOUNCE EXPANSION OF COLLABORATION

Capsida Biotherapeutics | February 27, 2023

news image

Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration. The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will...

Read More

Research

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed | February 15, 2021

news image

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More

Business Insights

QUALIGEN THERAPEUTICS ACQUIRES MAJORITY STAKE IN INFECTIOUS DISEASE DIAGNOSTICS TECHNOLOGY COMPANY NANOSYNEX

Qualigen Therapeutics, Inc. | June 03, 2022

news image

Qualigen Therapeutics, Inc. a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology. NanoSynex’s award winning technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to ...

Read More

Business Insights

ASYMCHEM ACQUIRES SNAPDRAGON CHEMISTRY

Asymchem | February 14, 2022

news image

Asymchem Laboratories Co., Ltd. a leading CDMO serving the global pharmaceutical and biotech industry, today announced its agreement to acquire Snapdragon Chemistry, Inc., a US-based chemical technology company providing industry-leading expertise in continuous manufacturing and early-stage chemical process development services to the pharmaceutical and fine chemical industries for US $57.94 million. This addition will significantly expand Asymchem's footprint in the US, offering customers a...

Read More
news image

PHARMACY MARKET, PHARMA TECH

CAPSIDA BIOTHERAPEUTICS AND ABBVIE ANNOUNCE EXPANSION OF COLLABORATION

Capsida Biotherapeutics | February 27, 2023

Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration. The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will...

Read More
news image

Research

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed | February 15, 2021

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More
news image

Business Insights

QUALIGEN THERAPEUTICS ACQUIRES MAJORITY STAKE IN INFECTIOUS DISEASE DIAGNOSTICS TECHNOLOGY COMPANY NANOSYNEX

Qualigen Therapeutics, Inc. | June 03, 2022

Qualigen Therapeutics, Inc. a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology. NanoSynex’s award winning technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to ...

Read More
news image

Business Insights

ASYMCHEM ACQUIRES SNAPDRAGON CHEMISTRY

Asymchem | February 14, 2022

Asymchem Laboratories Co., Ltd. a leading CDMO serving the global pharmaceutical and biotech industry, today announced its agreement to acquire Snapdragon Chemistry, Inc., a US-based chemical technology company providing industry-leading expertise in continuous manufacturing and early-stage chemical process development services to the pharmaceutical and fine chemical industries for US $57.94 million. This addition will significantly expand Asymchem's footprint in the US, offering customers a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us